Slim Adcomm Majority Boosts Sarepta’s Gene Therapy In Duchenne Muscular Dystrophy

Accelerated approval seems imminent after a majority of the US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted the risk-benefit balance supported it.

Sarepta SRP-9001 AC vote
An FDA official announces the advisory committee vote. • Source: Screenshot of FDA broadcast

Despite significant uncertainty about the efficacy of Sarepta Therapeutics, Inc.’s proposed gene therapy in Duchenne muscular dystrophy, the product took a big step toward an accelerated approval thanks to a slim majority of advisory committee votes.

Members of the US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee voted 8-6 that the risk-benefit...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers